Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

TY - JOUR

T1 - Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

AU - Rogoza, R. M.

AU - Westra, T. A.

AU - Ferko, N.

AU - Tamminga, J. J.

AU - Drummond, M. F.

AU - Daemen, T.

AU - Wilschut, J. C.

AU - Postma, M. J.

PY - 2009/7/30

Y1 - 2009/7/30

N2 - Cervical cancer is one of the most prevalent cancers among women worldwide. Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and 18 that cause cervical cancer is generally expected to significantly reduce the burden of cervical cancer disease. Here we estimate the costs, savings and health gains with the addition of HPV-16/18 vaccination to the already existing Dutch screening programme. In the base-case analysis, it was estimated that implementation of an HPV-16/18 vaccine would result in an incremental cost-effectiveness ratio (ICER) of (sic)22,700 per life-year gained (LYG). In sensitivity analysis, the robustness of our finding of favourable cost-effectiveness was established. The ICER appeared sensitive to the vaccine price, discount rate and duration of vaccine-induced protection. From our results, it validly follows that immunization of 12-year-old Dutch girls against HPV-16/18 infection is a cost-effective strategy for protecting against cervical cancer. (C) 2009 Elsevier Ltd. All rights reserved.

AB - Cervical cancer is one of the most prevalent cancers among women worldwide. Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and 18 that cause cervical cancer is generally expected to significantly reduce the burden of cervical cancer disease. Here we estimate the costs, savings and health gains with the addition of HPV-16/18 vaccination to the already existing Dutch screening programme. In the base-case analysis, it was estimated that implementation of an HPV-16/18 vaccine would result in an incremental cost-effectiveness ratio (ICER) of (sic)22,700 per life-year gained (LYG). In sensitivity analysis, the robustness of our finding of favourable cost-effectiveness was established. The ICER appeared sensitive to the vaccine price, discount rate and duration of vaccine-induced protection. From our results, it validly follows that immunization of 12-year-old Dutch girls against HPV-16/18 infection is a cost-effective strategy for protecting against cervical cancer. (C) 2009 Elsevier Ltd. All rights reserved.

KW - HPV

KW - Cost-effectiveness

KW - Cervical cancer

KW - The Netherlands

KW - RANDOMIZED CONTROLLED-TRIAL

KW - PARTICLE VACCINE

KW - HIGH-RISK

KW - INTRAEPITHELIAL NEOPLASIA

KW - SUSTAINED EFFICACY

KW - ECONOMIC-IMPACT

KW - YOUNG-WOMEN

KW - FOLLOW-UP

KW - INFECTION

KW - TYPE-16

UR - http://www.scopus.com/inward/record.url?scp=67650263391&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.05.085

DO - 10.1016/j.vaccine.2009.05.085

M3 - Article

SN - 0264-410X

VL - 27

SP - 4776

EP - 4783

JO - Vaccine

JF - Vaccine

IS - 35

ER -